Merck & Co Inc (NYSE:MRK) released topline data from the KEYFORM-007 Phase 3 study of the fixed-dose combination of ...

Merck (MRK) stock is in focus as a Phase 3 trial for its cancer drug Keytruda in colorectal cancer patients did not meet ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced that the European Medicines Agency's ...

Rahway, New Jersey Thursday, September 26, 2024, 09:00 Hrs [IST] ...

Also Read: Ca On Wednesday, Merck & Co Inc (NYSE:MRK) released topline data from the KEYFORM-007 Phase 3 study of the fixed-dose combination of favezelimab and pembrolizumab versus the standard of ...

The Oncologic Drugs Advisory Committee (ODAC) decided 10-2 with one abstention that PD-1 inhibitors do not have a favorable ...

An FDA advisory panel on Bristol Myers Squibb Opdivo and Merck Keytruda will examine if PD-L1 tumor expression should limit ...

Awardees were recognized for developing renewable lubricant base oils and ethyl acetate, more environmentally-friendly ...

A US Food and Drug Administration advisory committee meeting has recommended restricting the use of PD-1 inhibitors, in a ...

The Japanese MHLW has granted approval for MSD’s KEYTRUDA (pembrolizumab) for lung and urothelial cancer indications.

OrbusNeich Medical Group Holdings Limited ("OrbusNeich" or the "Group"; stock code: 6929), a major global medical device ...

Merck (MRK) announced the Japanese Ministry of Health, Labor and Welfare has approved new indications for KEYTRUDA or pembrolizumab, ...